Prostate Cancer Clinical Trial
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Must have histologically or cytologically confirmed adenocarcinoma of the prostate
Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Prior treatment with an androgen receptor (AR) degrader
Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 22 Locations for this study
Sarasota Florida, 34232, United States
Chicago Illinois, 60637, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States More Info
Grand Rapids Michigan, 49546, United States
Grand Rapids Michigan, 49546, United States More Info
New York New York, 10021, United States
New York New York, 10029, United States
New York New York, 10065, United States More Info
Durham North Carolina, 27710, United States
Philadelphia Pennsylvania, 19104, United States
Dallas Texas, 75235, United States
San Antonio Texas, 78229, United States
Madison Wisconsin, 53705, United States
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.